Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases

Patients with small and non–small cell lung cancer with bone metastases receiving extended interval dosing with zoledronic acid experienced comparable incidence and time to skeletal-related events as patients receiving standard dosing, according to data from a recent retrospective trial.